Categories
Featured Product

Lung Function Assessment in Patients with Persistent Asthma: Impact of Disease Severity and Acute Exacerbation Status © 

By Lawrence Rasouliyan, Amanda G. Althoff, and Danae A. Black | OMNY Health 

Understanding the Role of Lung Function in Asthma Management 

Lung function monitoring is important in the management of asthma, and it provides valuable information to clinicians on disease control and patient response. 

Pulmonary function tests are common tests conducted in clinical settings, yet they are infrequently documented as measurements in free-text notes or tabulated sources of real-world data. 

Meanwhile, disease severity and acute exacerbations are usually available based on the diagnosis codes such as the ICD-10.  

However, the association between coded severity and measured indices of lung function has not been well characterized in routine clinical care data on a large scale. 

This gap was filled by our team at OMNY Health, which analyzed the relationship of lung function measures with severity and exacerbation status in subjects with persistent asthma. 

Study Overview 

Using electronic health record (EHR) data from 2017 to 2024, we analyzed information from three integrated delivery networks included in the OMNY Health real-world data platform.  

Patients were included if they had an ICD-10 code for persistent asthma classified as mild, moderate, or severe—either with or without an acute exacerbation. The relevant ICD-10 codes used for classification are shown below. 

To be included, patients also needed at least one documented lung function measurement—specifically, forced expiratory volume in one second (FEV₁) percent predicted (pp), forced vital capacity (FVC) pp, or FEV₁/FVC pp—associated with an asthma-related encounter. 

Key Findings 

Out of approximately one million patients identified with an asthma ICD-10 code indicating severity and exacerbation status, 14,003 patients (across 31,463 encounters) had corresponding lung function data available. 

Across all severities, lung function metrics declined with increasing asthma severity, and patients experiencing exacerbations consistently had lower lung function compared to those without exacerbations.

What the Data Suggests 

Findings have shown a considerable decrease in mean lung function values because asthma severity increased—regardless of exacerbation status.  

Patients experiencing exacerbations had consistently lower FEV₁, FVC, and FEV₁/FVC metrics as compared to the ones with no exacerbations.  

Most interestingly, when we compared ICD-10–coded severity to typical clinical cutoffs for lung function, the correspondence was not strong enough.  

This undoubtedly suggests that ICD-10 coding alone may not fully capture physiological severity, emphasizing the importance of integrating structured and unstructured lung function data into real-world datasets. 

Why It Matters 

By leveraging structured EHR data, this study highlights the potential to better understand asthma progression and treatment outcomes across real-world populations. 

The results reinforce the value of using lung function metrics—not just diagnosis codes—to assess disease burden and guide more precise asthma management strategies. 

References 

  1. Levy ML, et al. NPJ Prim Care Respir Med. 2023;33(1):7. 
  1. Firoozi F, et al. Thorax. 2007;62(7):581–7. 
  1. Gronkiewicz C, et al. Chest. 2015;147(4):1152–1160. 
  1. Xie F, et al. JMIR AI. 2025;4:e69132. 

 

© 2025 OMNY Health  

Categories
News

OMNY Health Chosen to Present at Venture Atlanta 2025, the Southeast’s Premier Tech Conference

Now in its 18th year, Venture Atlanta has helped launch 930 companies, raise more than $8 billion in funding, and achieve $20.8 billion in successful exits to date 

 ATLANTA – September 11th, 2025 – OMNY Health is proud to announce its selection as one of the Southeast’s most promising tech companies to present at Venture Atlanta 2025. The event, to be held October 15-16 at The Woodruff Arts Center and Atlanta Symphony Hall, brings together visionary startups and growth-stage companies with hundreds of the nation’s top-tier investors. As the Southeast’s premier platform for tech innovation, growth, and capital access, Venture Atlanta continues to be a launchpad for companies shaping the future. 

Now in its 18th year, Venture Atlanta has helped launch over 930 companies, facilitating over $8 billion in funding and $20.8 billion in successful exits to date. This year, the event has expanded to include new founder pathways, curated networking, and procurement programming to attract over 1,600 attendees, including 450 investment funds from across the U.S. 

“We are incredibly honored to be selected to present at Venture Atlanta 2025. This city has become a hub for health tech innovation, and Venture Atlanta is the premier platform where the future of the industry gets shaped. To be recognized among a peer group of such promising, high-growth companies is a testament to our team and the critical infrastructure we are building. We look forward to sharing how OMNY’s healthcare data ecosystem will fuel the next generation of life-changing innovation.” 

As in previous years, Venture Atlanta 2025 is anticipated to be a sold-out event. 

“Venture Atlanta is where companies come to get discovered,” said Venture Atlanta CEO Allyson Eman. “To be selected in a year as competitive as this one speaks volumes about the strength and potential of these startups. These companies didn’t just stand out—they’re poised to break out. With hundreds of investors in the room and a highly curated audience, the visibility companies get here often leads directly to the funding, partnerships, and momentum they need to thrive. We’re incredibly proud to help founders gain the exposure and support that accelerates their path to success.” 

This year’s Venture Atlanta will once again bring together the Southeast’s most promising technology companies and the investors eager to discover them. With applications from across the region—including Alabama, Arkansas, Florida, Georgia, Kentucky, Louisiana, Maryland, North Carolina, South Carolina, Mississippi, Tennessee, Texas, Virginia, and Washington, D.C.—the 2025 conference offers a rare opportunity to see the region’s top innovators all in one place. 

Venture Atlanta boasts a roster of highly successful alumni, including Bark, CallRail, Car360, Flock Safety, Florence Healthcare, ParkMobile, Salesloft, Kabbage, Bitcoin Depot, PrizePicks, Stax, SingleOps, Pindrop, Terminus, and many others. 

To learn more about OMNY Health, visit www.omnyhealth.com.  For additional information about Venture Atlanta, to register for the event, or to view the conference schedule, please visit www.ventureatlanta.org.  

 

About Venture Atlanta 

Venture Atlanta, the Southeast’s technology innovation event, is where the region’s most promising tech companies meet the country’s top-tier investors. As the Southeast’s largest investor showcase helping launch 930 companies and raise over $8 billion in funding to date, the event connects the region’s top entrepreneurs with local and national investors and others in the technology ecosystem who can help them raise the capital they need to grow their businesses. The annual nonprofit event is a collaboration of the Atlanta CEO Council, Metro Atlanta Chamber, and the Technology Association of Georgia (TAG). For more information, visit www.ventureatlanta.org. For updates, follow us on Twitter and LinkedIn, and visit our blog

 

About OMNY Health 

OMNY Health™ is the leading healthcare ecosystem for compliant real-world data insights at scale. OMNY Health connects patients, providers, and life sciences companies by transforming vast amounts of de-identified electronic health record data, clinical notes, and claims data into robust, research-ready insights. Leveraging proprietary AI, NLP, and LLM technologies, OMNY Health accelerates therapeutic innovation, optimizes clinical development, and enhances patient care. For more information, visit www.omnyhealth.com